Does GLP-1 use lower breast cancer incidence?
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
Women taking GLP-1 drugs to lose weight and treat diabetes, including Ozempic, Wegovy, Mounjaro and Zepbound, had an approximately 30% lower risk of developing breast cancer.
Penn Medicine Reports 30% Drop in Breast Cancer Risk with Ozempic and Wegovy
A landmark study published June 2, 2026, in JCO Oncology Practice and simultaneously presented at the 2026 American Society of Clinical Oncology Annual Meeting by researchers at the University of Pennsylvania Perelman School of Medicine has produced findings that could reshape how America’s medical community thinks about GLP-1 receptor agonist drugs and how millions of women with obesity approach their own cancer risk. The study, led by Dr. Eliz…
Does GLP-1 use lower breast cancer incidence?
GLP 1 drugs and breast cancer risk: large cohort evidence A large cohort study reported an association between GLP 1 weight loss medications and a lower incidence of breast cancer. The study examined more than 110,000 women and found that those who took GLP 1 drugs were about 30% less likely to…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
